In one study that included 22 AML and higher-risk MDS patients, all exhibiting a deletion of 5q, including CXXC5, 13 patients demonstrated CXXC5 expression levels below 50% of those observed in the standard control group. The gene discussed is CXXC5; the disease is myelodysplastic syndrome.